The global idiopathic pulmonary fibrosis treatment market reached a value of US$ 3,278 Million in 2021. Looking forward, IMARC Group expects the market to reach US$ 5,268 Million by 2027, exhibiting at a CAGR of 7.89% during 2022-2027. More Info:- https://www.imarcgroup.com/idiopathic-pulmonary-fibrosis-treatment-market

1. Copyright © IMARC Service Pvt Ltd. All Rights Reserved
Global Idiopathic Pulmonary
Fibrosis Treatment Market
Research and Forecast Report 2022-
2027
Author: Elena Anderson
Marketing Manager
IMARC Group
© 2022 IMARC All Rights Reserved

2. Report Description
About IMARC Group
International Market Analysis Research and Consulting Group is a leading adviser on
management strategy and market research worldwide. We partner with clients in all regions
and industry verticals to identify their highest-value opportunities, address their most critical
challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological
developments for business leaders in pharmaceutical, industrial, and high technology
organizations. Market forecasts and industry analysis for biotechnology, advanced materials,
chemicals, food and beverage, travel and tourism, nanotechnology and novel processing
methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and
markets with close cooperation at all levels of the client organization. This ensures that our
clients achieve unmatchable competitive advantage, build more proficient organizations, and
secure lasting results.

3. Report Description
Report Description and Highlights
Global Idiopathic Pulmonary Fibrosis Treatment Market Research Report 2022-2027:
According to the latest report by IMARC Group, titled "Idiopathic Pulmonary Fibrosis Treatment
Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-
2027," the global idiopathic pulmonary fibrosis treatment market reached a value of US$ 3,278
Million in 2021.
Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease that causes scarring of the lungs,
reducing their oxygen delivering capacity. The chronic lung disease is progressive and irreversible in
nature as it continuously impacts the functioning of the lungs. It causes difficulty in breathing and
does not provide sufficient oxygen to different body parts. IPF can be diagnosed through chest
imaging studies, lung biopsies, pulmonary function tests, and antibody tests.
Thetreatment includes nintedanib and pirfenidone-based drugs that aid in lung functioning and
minimize the risk of acute respiratory deterioration. They are also offered along with oxygen therapy
and palliative care, which improve the chances of recovery and provide comfort to the patient.
Request for a PDF sample of this report: https://www.imarcgroup.com/idiopathic-pulmonary-
fibrosis-treatment-market/requestsample

4. Report Description
Report Description and Highlights
Global Idiopathic Pulmonary Fibrosis Treatment Market Trends:
The market is primarily driven by the rising geriatric population, which is susceptible tolung disorders.
Aging is considered the greatest risk factor for the development of IPF. Moreover, the growing
prevalence of fibrotic diseases, owing to changing lifestyles and heavy consumption of nicotine products
like cigarettes is also propelling the demand for IPF treatment. Besides this, major healthcare companies
are extensively investing in the development and commercialization of novel drugs, especially in
emerging economies, which is fueling the growth of the market.
The rising health consciousness among individuals regarding effective management strategies is also
creating a positive outlook for the market. Furthermore, increasing healthcare expenditures and
improving infrastructure arealso facilitating the market growth.
Looking forward, the market value is expected to reach US$ 5,268 Million by 2027, exhibiting a CAGR
of 7.89% during the forecast period (2022-2027).
View Report TOC, Figures and Tables: https://www.imarcgroup.com/idiopathic-pulmonary-fibrosis-
treatment-market

5. Report Description
Report Description and Highlights
Key Market Segmentation
The research report includes the following segments:
Breakup by Drug Class:
•MAPK Inhibitors
•Tyrosine Inhibitors
•Autotaxin Inhibitors
Breakup by End User:
•Hospitals
•Long-term Care Facilities
•Others
Breakup by Region:
•North America
•Asia Pacific
•Europe
•Latin America
•Middle East and Africa

6. Report Description
Report Description and Highlights
Competitive Landscape with Key Players:
•AdAlta Pty Ltd
•Angion Biomedica Corp
•Boehringer Ingelheim International GmbH (C. H. Boehringer Sohn AG & Co. KG)
•Bristol-Myers Squibb Company
•Cipla Inc
•F. Hoffmann-La Roche AG (Roche Holding AG)
•Fibrogen Inc
•Galapagos NV
•Liminal BioSciences Inc
•Medicinova Inc
•Merck & Co. Inc
•Novartis AG
•Vectura Group Plc

7. Report Description
Key Questions Answered in the Report
1. How has the global idiopathic pulmonary fibrosis treatment market performed so far and how
will it perform in the coming years?
2. What has been the impact of COVID-19 on the global idiopathic pulmonary fibrosis treatment
market?
3. What are the key regional markets?
4. What is the breakup of the market based on the drug class?
5. What is the breakup of the market based on the end user?
6. What are the various stages in the value chain of the industry?
7. What are the key driving factors and challenges in the industry?
8. What is the structure of the global idiopathic pulmonary fibrosis treatment market and who are
the key players?
9. What is the degree of competition in the industry?

8. Report Description Table of Contents
1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Idiopathic Pulmonary Fibrosis Treatment Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

9. Report Description Table of Contents
6 Market Breakup by Drug Class
6.1 MAPK Inhibitors
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Tyrosine Inhibitors
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Autotaxin Inhibitors
6.3.1 Market Trends
6.3.2 Market Forecast
7 Market Breakup by End User
7.1 Hospitals
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Long-term Care Facilities
7.2.1 Market Trends
7.2.2 Market Forecast
Click here to visit the complete table of content with list of figures and tables:
https://www.imarcgroup.com/idiopathic-pulmonary-fibrosis-treatment-market/toc

10. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

11. A partial List of our Clients
We are the trusted business partners to the
world's leading corporates, governments, and
institutions
Partial List of Clients

12. Report Description
Report Description and Highlights
© 2022 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of
International Market Analysis Research and Consulting (IMARC). No part of this publication may be
reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be
used in any form or by and means graphic electronic or mechanical, including photocopying, recording,
taping or by information storage or retrieval, or by any other form, without the express consent of
International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been
based on information and sources believed to be accurate and reliable at the time of publishing.
International Market Analysis Research and Consulting makes no representation of warranty of any kind as to
the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any
loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market
Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of
their respective companies.

13. FOR MORE DETAILS
Visit us at :
Stay With Us:
TELEPHONE: +1-631-791-1145
E-MAIL: sales@imarcgroup.com
https://www.imarcgroup.com
Contact Us